

Project ID	Title	Project PI	Institution	Location	Award Amount	Start Date	End Date	Tumor Type(s)	Project Wiki
NTAP-2018-014	Pilot Study of Factors Impacting Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials	Staci Martin	NCI	Bethesda	\$138,675	10/1/18	9/30/21	plexiform neurofibromas (pNF)	
NTAP-2018-013	Imaging predictors of malignant peripheral nerve sheath tumors	Ina Ly	Harvard	Cambridge	\$625,335	9/1/18	10/31/21	plexiform neurofibromas (pNF), atypical neurofibroma (AN), malignant peripheral nerve sheath tumor	https://www.synapse.org/#!Synapse:syn17098100/wiki/587913
NTAP-2018-012	THE ROLE OF GABA IN THE WORKING MEMORY IMPAIRMENTS IN NEUROFIBROMATOSIS TYPE 1	Shruti Garg	University of Manchester	Manchester	\$555,737	8/1/18	7/31/21	ADFACT NF1 cognitive deficiency	https://www.synapse.org/#!Synapse:syn17100988/wiki/587928
NTAP-2018-011	A Nerve Sheath Tumor Bank from Patients with NF1	Christine Pratilas	Johns Hopkins University	Baltimore	\$541,000	6/1/18	5/31/21	plexiform neurofibroma, cutaneous neurofibroma, MPNST	https://www.synapse.org/#!Synapse:syn4939902/wiki/235907
NTAP-2018-010	Evaluation of Erk1/2, CDK4/6, and PI3K Inhibition in Plexiform Neurofibromas Utilizing a Murine Pre-Clinical Model of Neurofibromatosis Type 1	D. Wade Clapp	Indiana University	Indianapolis	\$253,121	6/1/18	8/31/19	plexiform neurofibromas (pNF)	
NTAP-2018-009	Use of the mouse model of cNFs for identification of cells of origin and drug screening studies	Piotr Topilko	INSERM	Paris	\$396,000	4/1/18	12/30/20	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374337/wiki/488810
NTAP-2018-008	Genetic Studies of Neurofibromatosis	Peggy Wallace	University of Florida	Gainesville	\$369,000	7/1/18	6/30/21	Cutaneous neurofibromas	https://www.synapse.org/#!Synapse:syn11374357/wiki/488836
NTAP-2018-007	Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas	Raymond Mattingly	Wayne State University	Detroit	\$394,370	4/1/18	3/31/22	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374357/wiki/488836
NTAP-2018-006	Generation, characterization and epigenetic memory of cNF-derived iPSCs and dissection of Schwann cell-fibroblast interactions	Eduard Serra	The Institute for Health Science Research Germans Trias i Pujol (IGTP) - Washington University	Barcelona	\$274,450	3/1/18	2/28/21	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374353/wiki/488824
NTAP-2018-005	Leveraging human iPSCs to determine the impact of patient-derived NF1 gene mutations on peripheral sensory neuron-driven Schwann cell growth	David Gutmann	Washington University	St. Louis	\$340,044	7/1/18	6/30/21	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374345/wiki/488824
NTAP-2018-004	Microenvironmental targets of cutaneous neurofibromas: T-cells and mast cells as tumor contributions	Juha and Sirkku Peltonen	University Tirkku	Tirkku	\$314,270	3/1/18	2/28/21	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374341/wiki/488819
NTAP-2018-003	A 3D Cutaneous Neurofibroma Model for Automated High-Throughput Drug Screenings	Alice Soragni	UCLA	Los Angeles	\$286,000	2/1/18	1/31/20	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374354/wiki/488822
NTAP-2018-002	Cutaneous Neurofibroma: Models, Biology and Translation	Lu Le	University of Texas Southwestern Medical Center	Dallas	\$396,000	2/1/18	1/31/21	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374333/wiki/488806
NTAP-2018-001	Modeling cNF with human Schwann cells via tunable and reversible control of NF1 protein	Gabsang Lee	Johns Hopkins University	Baltimore	\$337,150	2/1/18	1/31/21	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn11374349/wiki/488800
NTAP-2017-006	High-Resolution Ultrasonography and Optical Frequency Domain Imaging for Measurement and Characterization of Cutaneous Neurofibromas in Patients with NF1	Scott Plotkin	Harvard	Cambridge	\$541,424	10/1/17	9/30/19	Cutaneous neurofibromas (cNF)	
NTAP-2017-005	Novel Therapeutics in Malignant Peripheral Nerve Sheath Tumor (MPNST)	Ping Chi	Memorial Sloan Kettering Cancer Center	New York	\$778,708	7/1/17	6/30/20	MPNST	https://www.synapse.org/#!Synapse:syn11681835/wiki/507239
NTAP-2017-004	Development of a Preclinical NF1-MPNST Platform Suitable for Precision Oncology Drug Discovery and Evaluation	Angela Hirbe	Washington University	St. Louis	\$646,932	7/1/17	6/30/20	MPNST	https://www.synapse.org/#!Synapse:syn11638893/wiki/504183
NTAP-2017-003	Search of the molecular mechanisms sustaining plexiform neurofibroma formation in a novel three-dimensional in vitro model	Federica Chiara	Pavoda University	Padova	\$76,780	3/1/17	2/28/18	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn8016577/wiki/411636
NTAP-2017-002	TRAPping the metabolic adaptations of plexiform neurofibroma	Andrea Rasola	Pavoda University	Padova	\$290,015	1/1/17	12/31/21	plexiform neurofibroma, MPNST	https://www.synapse.org/#!Synapse:syn8016650/wiki/411639
NTAP-2017-001	TRAPping the metabolic adaptations of plexiform neurofibroma	Giorgio Colombo	University of Milan	Milan	\$149,985	1/1/17	12/31/19	plexiform neurofibroma, MPNST	https://www.synapse.org/#!Synapse:syn8016650/wiki/411639
NTAP-2016-005	Modeling signaling networks of NF1-deficient Schwann cells and plexiform neurofibromas using mass spectrometry-based proteomics	James Walker	Harvard	Cambridge	\$360,621	12/1/16	11/30/19	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn8016599/wiki/411637
NTAP-2016-004	A Robust Plexiform Neurofibroma Model for Preclinical Drug Screening	Lu Le	University of Texas, Southwestern Medical Center	Dallas	\$197,670	11/1/16	2/28/18	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn8016635/wiki/411638

NTAP-2016-003	Testing the Pharmacologic role of Molecular Target inhibition on Plexiform Neurofibromas in a Genetically Engineered Mouse Model that closely Phenocopies Human Neurofibromatosis Type 1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial	D. Wade Clapp	Indiana University	Bloomington	\$211,352	9/1/16	8/31/19	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn8012599/wiki/411635
NTAP-2016-002	A PHASE I/II STUDY OF THE MITOGEN ACTIVATED PROTEIN KINASE (MEK) 1 INHIBITOR SELUMETINIB (AZD6244; HYD SULFATE) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPFRARI F P I FXIFORM	Ashley Cannon	University of Alabama, Birmingham	Birmingham	\$451,584	7/1/16	6/30/19	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn8012530/wiki/411605
NTAP-2016-001B	A PHASE I/II STUDY OF THE MITOGEN ACTIVATED PROTEIN KINASE (MEK) 1 INHIBITOR SELUMETINIB (AZD6244; HYD SULFATE) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)	Michael Fischer	Childrens Hospital of Philadelphia	Philadelphia	\$1,002,400	1/1/16	12/31/19	plexiform neurofibroma	
NTAP-2016-001A	A PHASE I/II STUDY OF THE MITOGEN ACTIVATED PROTEIN KINASE (MEK) 1 INHIBITOR SELUMETINIB (AZD6244; HYD SULFATE) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)	Brian Weiss	Cincinnati Children Hospital	Cincinnati	\$890,944	1/1/16	12/31/19	plexiform neurofibroma	
NTAP-2015-008	Using PNF-derived NF1(+/-) and NF1 (-/-) iPS cells: understanding PNF-cell of origin, first steps in malignant progression and specific inhibition of NF1 (-/-) cell proliferation	Eduard Serra	The Institute for Health Science Research Germans Trias i Pujol (IGTP) - PMPPC	Barcelona	\$381,944	12/1/15	5/31/19	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939918/wiki/235915
NTAP-2015-007	A Nerve Sheath Tumor Bank from Patients with NF1	Tom Loeb	Johns Hopkins University	Baltimore	\$247,270	12/1/15	5/31/18	plexiform neurofibroma, cutaneous neurofibroma, MPNST	
NTAP-2015-006	Development of a novel treatment approach to Neurofibromatosis Type 1-related MPNST using genetically engineered Clostridium novyi-NT.	Verena Staedtke	Johns Hopkins University	Baltimore	\$739,154	10/1/15	9/30/19	MPNST	https://www.synapse.org/#!Synapse:syn4939884/wiki/235898
NTAP-2015-005	Transition to confirmatory and secondary screening of plexiform neurofibroma models in 96-well format (Supplemental project)	Raymond Mattingly	Wayne State University	Detroit	\$41,811	8/1/15	10/31/16	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939916/wiki/235914
NTAP-2015-004	Combination Index Validation Studies (2 drug combinations)	D. Wade Clapp	Indiana University	Bloomington	\$13,274	7/15/15	12/31/15	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939876/wiki/235910
NTAP-2015-003	The Role of MEK-inhibitors for the Prevention and Treatment of Optic Pathway Gliomas in an Nf1 Deficient Mouse Model	Miriam Bornhorst	Childrens National Medical Center	Bethesda	\$631,851	7/1/15	6/30/19	optic pathway glioma	https://www.synapse.org/#!Synapse:syn4939914/wiki/235913
NTAP-2015-002	PAIN, Acceptance and Commitment Training for Chronic Pain in Adolescents and Young Adults with Neurofibromatosis Type I and Plexiform Neurofibromas: A	Staci Martin	National Institutes of Health	Bethesda	\$251,272	5/5/15	11/4/18	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939896/wiki/235904
NTAP-2015-001	SUZ12, Prevention trial for tumor formation in mice modeling NF1 microdeletion patients	Thomas de Raedt	Harvard	Cambridge	\$76,176	2/12/15	2-29-16	MPNST	https://www.synapse.org/#!Synapse:syn4939908/wiki/235910
NTAP-2014-009	Targeting the mechanisms underlying cutaneous neurofibroma formation in NF1: a clinical	Matthew Steensma	Spectrum Health	Grand Rapids	\$545,954	7/1/14	6/30/18	Cutaneous neurofibromas (cNF)	https://www.synapse.org/#!Synapse:syn4939910/wiki/235903
NTAP-2014-008	Imaging Biomarkers of Neurofibromatosis Type 1-Associated Optic Pathway Glioma	Peter de Blank	Case Western Reserve University	Cleveland	\$33,683	7/1/14	12-31-24	optic pathway glioma	https://www.synapse.org/#!Synapse:syn4939894/wiki/235903
NTAP-2014-007	Regulation of GCPII for the Diagnosis and Treatment of Neurofibromas	Nancy Ratner	Cincinnati Children Hospital	Cincinnati	\$36,394	5/1/14	4-30-15	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939880/wiki/235896
NTAP-2014-006	Development of a needs-based quality of life Patient Reported Outcome measure specific to patients with NF1-associated pNFs	Stephen McKenna	Galen Group	Manchester	\$224,504	3/1/14	1/1/18	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939892/wiki/235902
NTAP-2014-005	Identification of Neurofibroma Growth and Drug Resistance Pathways	Nancy Ratner	Cincinnati Children Hospital	Cincinnati	\$318,959	2/1/14	1-31-16	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939878/wiki/235895
NTAP-2014-004	Development of a Child Neurofibromatosis Type 1 Health Related Quality of Life Measure	Nancy Swigonski	Indiana University	Bloomington	\$329,421	2/1/14	1/31/17	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939888/wiki/235900
NTAP-2014-003	Development of Patient Reported Outcomes System for Patients with NF1-Associated Plexiform Neurofibromas using Mixed Method Approach	Jin-Shei Lai	Northwestern University	Evanston	\$348,238	2/1/14	5/31/18	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939904/wiki/235900
NTAP-2014-002	The Development and Validation of PRO Measures to Assess Pain in Individuals with NF1 and pNF	Pam Wolters	National Institutes of Health	Bethesda	\$467,503	1/23/14	2/28/19	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn7217946/wiki/405450
NTAP-2014-001	Development of a novel plexiform neurofibroma farming system for 96-well plate drug screening	Karlyne Reilly	National Cancer Institute	Bethesda	\$152,600	1/1/14	12/31/16	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939904/wiki/235900
NTAP-2013-007	Regulation of GCPII for the Diagnosis and Treatment of Neurofibromas	Anat Stemmer-Rachamimov	Harvard	Cambridge	\$21,710	12/1/13	11-20-14	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939904/wiki/235900
NTAP-2013-006	Regulation of GCPII for the Diagnosis and Treatment of Neurofibromas	Barbara Slusher	Johns Hopkins University	Baltimore	\$311,325	7/26/13	7-26-15	plexiform neurofibroma	https://www.synapse.org/#!Synapse:syn4939904/wiki/235900

NTAP-2013-005	Development of a PNF Cellular Assay for HTS	Peggy Wallace	University of Florida	Gainesville	\$361,303	6/1/13	5/31/16	plexiform neurofibroma	https://www.synapse.org/#!/Synapse:syn7239479/wiki/405899
NTAP-2013-004	Exploring the plexiform neurofibroma interactome	Jianqing Wu	Cincinnati Children Hospital	Cincinnati	\$322,200	5/15/13	11-14-15	plexiform neurofibroma	https://www.synapse.org/#!/Synapse:svn4939890/wiki/2
NTAP-2013-003	Plexiform Neurofibroma Model Systems for Preclinical Drug Screening	Raymond Mattingly	Wayne State University	Detroit	\$330,000	5/1/13	4-30-16	plexiform neurofibroma	https://www.synapse.org/#!/Synapse:syn7217928/wiki/405449
NTAP-2013-002	Perpetuating NF1+/- and NF1-/- plexiform neurofibroma-derived tumor cells through the generation of induced pluripotent stem (iPS) cells	Eduard Serra	The Institute for Health Science Research Trias i Pujol (IGTP) - IMIBIC	Barcelona	\$299,500	5/1/13	8-31-15	plexiform neurofibroma	https://www.synapse.org/#!/Synapse:syn7231973/wiki/405895
NTAP-2013-001	A primary plexiform neurofibroma cell culture model for use in cell-based high-throughput screens	Luis Parada	Memorial Sloan Kettering Cancer Center	New York	\$165,000	5/1/13	4-30-15	plexiform neurofibroma	https://www.synapse.org/#!/Synapse:syn7217935/wiki/405449